Keratoconjunctivitis is an indication for drug development with over 180 pipeline drugs currently active. According to GlobalData, preregistered drugs for Keratoconjunctivitis have a 88.89% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Keratoconjunctivitis compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Keratoconjunctivitis overview
Keratoconjunctivitis sicca (KCS), also known as dry eye syndrome (DES), dry eye disease, and keratitis sicca, is a multifactorial disease of the ocular surface caused by a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular surface inflammation and damage, and neurosensory abnormalities.
For a complete picture of PTSR and LoA scores for drugs in Keratoconjunctivitis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.